PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 1, 2026Cancer ImagingOpen Access

Early radiological response pattern predicts long-term response in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMarkus KleinbergerMMMaximilian J. MairJBJ Berger

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates early radiological response patterns predicting long-term outcomes in non-small cell lung cancer patients, indicating valuable prognostic tools.

Key Points

  • The study aims to assess whether early radiological response patterns can predict long-term outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
  • Prospective enrollment of 122 patients with advanced non-small cell lung cancer (03/2019 - 03/2023).
  • Imaging assessed per iRECIST, focusing on changes in sum of diameters (SoD) between baseline and first restaging (8-12 weeks).
  • Endpoints included associations between early radiological response and disease control, best overall response, overall survival, and progression-free survival.
  • 32.8% of patients were best overall response (BOR) responders, and 47.5% achieved durable clinical benefit (DCB).
  • Early SoD reduction predicted DCB (p > 0.05, AUC 0.764) and BOR (p < 0.01, AUC 0.701).
  • First-line ICI showed greater early shrinkage (p < 0.001) compared to later-line therapy, which reduced response odds (BOR: OR 0.34; DCB: OR 0.38).

Cite This Study

Kleinberger et al. (2026) studied this question.

synapsesocial.com/papers/6a1d218f02fbce91306378aahttps://doi.org/10.1186/s40644-026-01048-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic factors for survival in NSCLC treated with immunotherapy: An institutional analysis.2024
  2. 2Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria.2024
  3. 3Clinical predictors of response to single‑agent immune checkpoint inhibitors in chemotherapy‑pretreated non‑small cell lung cancer2024 · 4 citations
  4. 4Peripheral Blood Biomarkers Predicting the Efficacy of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Retrospective Study2024
  5. 5Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy2024 · 4 citations